We recently published an article titled, Jim Cramer’s Latest Lightning Round: 12 Stocks to Watch. In this article, we are ...

Failed to import article template. Reason: Failed to fetch dynamically imported module: ...

Equities research analysts at Zacks Research reduced their Q3 2024 earnings estimates for AbbVie in a research note issued on ...

Narus Financial Partners LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 8.4% in the 3rd quarter, ...

We recently published a list of 10 Best Medical Stocks to Buy Now. In this article, we are going to take a look at where ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

David Risinger, an analyst from Leerink Partners, maintained the Hold rating on AbbVie (ABBV – Research Report). The associated price ...

Vyalev is the first subcutaneous 24-hour continuous infusion of levodopa-based therapy for advanced Parkinson’s disease.

In a report released today, Christopher Raymond from Piper Sandler maintained a Buy rating on AbbVie (ABBV – Research Report), with a ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and ...

AbbVie Inc. (NYSE: ABBV) is rewarding its shareholders once again with a quarterly dividend of $1.55, payable on Tuesday Oct.

On Thursday, AbbVie Inc (ABBV) stock saw a decline, ending the day at $188.57 which represents a decrease of $-1.89 or -0.99% from the prior close of $190.46. The stock opened at $190.54 and touched a ...